Fundraising Fox
Minerva Neurosciences
NASDAQ: NERVWaltham, US · Massachusetts corporation · 5 known investors
Find your way into Minerva Neurosciences
Sign up to see every warm intro you have to Minerva Neurosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Minerva Neurosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders. It focuses on designing clinical trials with endpoints tied to patient benefit.
Founders & leadership
JR
Joseph ReillyExecutive
RL
ML
Mark LevineExecutive
Board
MO
FD
JV
Jan Van HeekBoard director
NV
Nico VandervelpenBoard director
Investors · 5
Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M
How we know: Vivo Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Care CapitalreportedPrinceton
How we know: the S-1 prospectus · Not right? Tell us
Index VenturesreportedSan Francisco · $540K – $10.8M
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$32M disclosed across 2 of 4 rounds · 2015–2025
▶$20MofferedJul 2023 · 4 investors · BiotechnologyRule 506(b)
▶$20MofferedJul 2023 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fouzia Laghrissi-ThodeDirector
- Jan van HeekDirector
- David KupferDirector
- Jeryl HillemanDirector
- Hans Peter HaslerDirector
- Geoffrey RaceExecutive Officer
- Remy LuthringerExecutive Officer, Director
- Frederick AhlholmExecutive Officer
- Offering amount
- $20M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMar 2016 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedMar 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fouzia Laghrissi-ThodeDirector
- Fred AhlholmExecutive Officer
- David KupferDirector
- Geoff RaceExecutive Officer
- Mark LevineExecutive Officer
- Remy LuthringerExecutive Officer, Director
- Joseph ReillyExecutive Officer
- Jan Van HeekDirector
- Francesco De RubertisDirector
- Michele OllierDirector
- Nico VandervelpenDirector
- Marc BeerDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$31MraisedMar 2015 · 22 investors · BiotechnologyRule 506(b)
▶$31MraisedMar 2015 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jan Van HeekDirector
- Joseph ReillyExecutive Officer
- Nico VandervelpenDirector
- Geoff RaceExecutive Officer
- Fred AhlholmExecutive Officer
- Remy LuthringerExecutive Officer, Director
- Mark LevineExecutive Officer
- Michele OllierDirector
- Francesco De RubertisDirector
- Marc BeerDirector
- Offering amount
- $31M
- Amount sold
- $31M
- Sales commissions
- $2.2M
- Placement agents
- Jefferies LLC
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$109.7Mvaluation at IPOJul 2014 · $6.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 4
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies working in the same space as Minerva Neurosciences.
Frequently asked questions
- What does Minerva Neurosciences do?
- Minerva Neurosciences is a clinical-stage biopharmaceutical company developing product candidates for central nervous system disorders. It focuses on designing clinical trials with endpoints tied to patient benefit.
- Who are Minerva Neurosciences's investors?
- Minerva Neurosciences's investors include Vivo Capital, Care Capital, Index Ventures, LifeSci Venture Partners, Medicxi.
- How much funding has Minerva Neurosciences raised?
- Minerva Neurosciences has disclosed $32M raised across 2 of its 4 known rounds.
- Where is Minerva Neurosciences headquartered?
- Minerva Neurosciences is headquartered in Waltham, US.